
The World Health Organization has a new report showing dramatic decreases in malaria in Rwanda and Ethiopia following the large-scale distribution of long-lasting insecticidal nets (LLINs) and artemisinin-combination therapy drugs (ACTs) :
Our investigation showed that declines of malaria cases and deaths
were dramatic in Rwanda and Ethiopia (>50%) and occurred within 12-24
months of nationwide 11 distribution of LLINs and ACTs. In fact,
declines in in-patient cases and out-patient laboratory-confirmed
cases occurred within 60 days of nationwide distribution in Rwanda
(Figure 4). In both Rwanda and Ethiopia, similar declines (>50%)
occurred for impact measures that required malaria laboratory
testing–out-patient laboratory-confirmed cases and malaria slide
positivity rate. In Rwanda, all 19 health facilities performed malaria
smears on all suspected malaria cases. The decline in in-patient and
out-patient laboratory-confirmed malaria cases occurred in the face of
increases in out-patient and inpatient non-malaria cases in most
countries during 2001 to 2004-2005 due to introduction of health
insurance schemes, resolving civil conflict, and improvement of health
services.
The Washington Post story has some reactions:
“This is a genuinely historic achievement,” said Richard G.A. Feachem, former director of the Global Fund to Fight AIDS, Tuberculosis and Malaria who is now the director of the Global Health Group at the University of California at San Francisco. “This is not theoretical. We do not have to wait for a vaccine or new drugs. If we implement today’s technologies aggressively on a national scale, we will have a big impact.”
And The Economist reports
Based on the new results, Dr Kochi reckons that a five-year campaign costing about $10 billion would be enough to bring malaria under control in most of Africa, reducing the death rate to a matter of thousands a year.
Eliminating malaria altogether, though, would be a far harder task, involving destroying mosquitoes in the remaining pockets of infection. That is controversial: some — not least Dr Kochi — see it as a dangerous distraction until the easier job of bringing the disease under control is completed. Others want to aim straight away for elimination. In the long run, that should surely be the objective. But, as the old saying has it, the best can often turn out to be the enemy of the good. And the good now looks to be in sight.